Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure

Nakata, Tomoaki; Wakabayashi, Takeru; Kyuma, Michifumi; Takahashi, Toru; Tsuchihashi, Kazufumi; Shimamoto, Kazuaki

doi:10.1007/s00259-004-1624-8

Cited by 61 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a heterogeneous population of patients with heart failure, the most important determinant of cardiac uptake of 123 I-MIBG is the degree of impairment of the norepinephrine transporter function in presynaptic adrenergic neurons [2][3][4][5][6][7][8][9][10]. As such, considerable variation in late H/M ratio would be expected between patients with otherwise similar clinical presentations (NYHA class, LVEF, etc).…”

Section: Acquisition Parametersmentioning

confidence: 99%

“…In the past two decades, a large number of investigators have demonstrated decreased myocardial 123 I-MIBG uptake in patients with chronic heart failure (CHF) and have shown that those with the lowest uptake tend to have the poorest prognosis [2][3][4][5][6][7][8][9][10][11][12]. There have also been findings suggesting that abnormalities of myocardial 123 I-MIBG uptake may be predictive of increased risk of ventricular arrhythmia and sudden cardiac death [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

How to use myocardial 123I-MIBG scintigraphy in chronic heart failure

Denis

Carrió

Verberne

2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: Acquisition Parametersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

How to use myocardial 123I-MIBG scintigraphy in chronic heart failure

Denis

Carrió

Verberne

2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…-MIBG values have been demonstrated by numerous studies to have prognostic values in congestive heart failure patients [7,10,17]. Although some study were conducted by ME collimator, many hospitals now continue to use low-energy collimators, and most of the previous data were accumulated by using low-energy collimators.…”

Section: Imentioning

confidence: 99%

“…Parameters obtained with late MIBG scintigraphy images such as heart/mediastinum (H/M) ratio and washout rate can be used as indicators for sympathetic activity. Patients with the lowest uptake of MIBG have the poorest prognosis [10,17]. Normal value of H/M differs in each institution [3].…”

mentioning

confidence: 99%

Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera–collimator combinations

Matsuo

Nakajima

Okuda

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…17 In heart failure, variations in cardiac 123 I-mIBG uptake and washout correlate with the risk of future adverse cardiac events 19 and therapeutic interventions in heart failure patients have been shown to lead to increases in uptake. [20][21][22] These findings suggest that 123 I-mIBG scintigraphy can reflect dynamic changes in adrenergic function in the heart.…”

mentioning

confidence: 99%

123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?

George

Bhambhvani

Oparil

2017

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

See related article, pp. 363-371Among patients with treatment-resistant hypertension, transcatheter renal denervation has been shown to reduce blood pressure (BP) in a number of uncontrolled, unblinded clinical trials.1 However, in a prospective, single-blind, randomized trial that compared transcatheter renal denervation to a sham procedure, there was no significant difference in systolic BP between the two treatment arms at 6 months follow-up.2 Proposed reasons for the lack of benefit include a substantial placebo effect related to the procedure, differences in medication adherence such that the sham-treated control group may have taken more antihypertensive medications, operator inexperience with transcatheter renal denervation, and performance of an inadequate number of ablations in each renal artery.3 It has been postulated that operator inexperience and performance of too few ablations may have led to incomplete denervation and therefore an inadequate BP response to the procedure. The absence of a readily available methodology to define completeness of transcatheter renal denervation in humans remains as an unmet need in defining the potential role of the procedure in clinical practice.The contribution of increased renal sympathetic tone to the pathophysiology of hypertension has been known for decades. Surgical renal denervation in hypertensive animal models has been shown to cause significant decreases in BP compared to sham controls. 4 A commonly employed method of surgical denervation involves stripping the adventitia from the renal artery of hypertensive rats and exposing the artery to phenol, a compound that irreversibly blocks neural conduction. 5Renal norepinephrine (NE) content measured at specified time points after surgical denervation in hypertensive rats has been shown to decrease dramatically (94% reduction compared to sham-controlled rats at 1 week; P \ 0.001), suggesting complete ablation of the renal nerves. A positive correlation was also shown between absolute change in BP after denervation and renal NE content in denervated animals (r = 0.80, P \ 0.001). 4In the clinical research setting, a number of methods have been utilized to assess the completeness of renal denervation in hypertensive humans. The most promising and best characterized are the measurements of muscle sympathetic nerve activity (MSNA), renal NE spillover rate, and assessment of sympathetically mediated responses to electrical stimulation of the renal artery before and after denervation.6-8 Assessment of MSNA is minimally invasive and entails percutaneous insertion of a recording electrode into a superficial nerve (peroneal or radial), allowing direct recording of postganglionic sympathetic neural bursts. MSNA reflects moment-to-moment sympathetic outflow from the central nervous system to either skeletal muscle or skin, but does not provide direct information on sympathetic outflow to the kidney or heart. 9Renal NE spillover is assessed by infusing small doses of radiolabeled NE intravenously and measuring its level in...

show abstract

Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure

Cited by 61 publications

References 19 publications

How to use myocardial 123I-MIBG scintigraphy in chronic heart failure

How to use myocardial 123I-MIBG scintigraphy in chronic heart failure

Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera–collimator combinations

123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?

Contact Info

Product

Resources

About